SCHEMBL5034355

SCHEMBL5034355

C=CCNC(=O)Nc1scc(C)c1C(=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 1/20 0.48
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ATM Q13315 1/20 0.44
ALDH1A1 P00352 8/20 0.42
LMNA P02545 5/20 0.42
MAPT P10636 3/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALOX12 P18054 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
NPSR1 Q6W5P4 4/20 0.42
POLB P06746 2/20 0.42
TP53 P04637 1/20 0.42
GAA P10253 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2984306 0.85 ALDH1A1 (0.52) GSTO1MEN1KMT2AATMALDH1A1
SCHEMBL2979294 0.83 LMNA (0.48) GSTO1MEN1KMT2AATMALDH1A1
SCHEMBL2991353 0.82 MEN1 (0.55) GSTO1MEN1KMT2AATMALDH1A1
SCHEMBL2989345 0.81 LMNA (0.51) GSTO1MEN1KMT2AATMALDH1A1
SCHEMBL2992373 0.81 MEN1 (0.45) GSTO1MEN1KMT2AATMALDH1A1
SCHEMBL10731479 0.81 ALDH1A1 (0.51) GSTO1MEN1KMT2AATMALDH1A1
SCHEMBL2993917 0.81 NPSR1 (0.46) GSTO1MEN1KMT2AATMALDH1A1
SCHEMBL18097642 0.81 LMNA (0.46) GSTO1MEN1KMT2AATMALDH1A1
SCHEMBL18096913 0.80 ALDH1A1 (0.45) GSTO1MEN1KMT2AATMALDH1A1
SCHEMBL18097073 0.80 MAPT (0.45) GSTO1MEN1KMT2AATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989210-A2 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2008-11-12 EP disclosed
WO-2007103776-A2 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-09-13 WO disclosed
US-20070208040-A1 e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction GILEAD PALO ALTO, INC. 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208040-A1 e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction CHRNE, CHRNA3, CHRNA1 GSTO1 768/4885MEN1 4882/4885KMT2A 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.